Identification of different subtypes of breast cancer using tissue microarray

Romanian Journal of Morphology and Embryology

Volumn 52, Issue 2, 2011, Pages 669-677

  Munirah, M A ^a   Siti Aishah, M A ^a   Reena, M Z ^a   Sharifah, N A ^a   Rohaizak, M ^a   Norlia, A ^a   Rafie, M K M ^b   Asmiati, A ^b   Hisham, A ^b   Fuad, I ^a   Shahrun, N S ^a   Das, S ^a  

^a UNIVERSITI KEBANGSAAN MALAYSIA MEDICAL CENTER   (Malaysia)

^b PUTRAJAYA HOSPITAL   (Malaysia)

Author keywords

Breast cancer; Estrogen receptor; HER2; Immunohistochemistry; Keratins; Progesterone receptor

Indexed keywords

TUMOR MARKER;

ARTICLE; BREAST TUMOR; CANCER INVASION; CLASSIFICATION; DEMOGRAPHY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; PATHOLOGY; TISSUE MICROARRAY;

BREAST NEOPLASMS; DEMOGRAPHY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 79959350420     PISSN: 12200522     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Böcker W, Moll R, Poremba C, Holland R, Van Diest PJ, Dervan P, Bürger H, Wai D, Ina Diallo R, Brandt B, Herbst H, Schmidt A, Lerch MM, Buchwallow IB, Common adult stem cells in the human breast give rise to glandular and myoepithelial cell lineages: a new cell biological concept, Lab Invest, 2002, 82(6):737-746.
2. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lønning P, Børresen-Dale AL, Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications, Proc Natl Acad Sci U S A, 2001, 98(19):10869-10874.
3. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM, Gilks CB, van de Rijn M, Perou CM, Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma, Clin Cancer Res, 2004, 10(16):5367-5374.
4. van de Rijn M, Perou CM, Tibshirani R, Haas P, Kallioniemi O, Kononen J, Torhorst J, Sauter G, Zuber M, Köchli OR, Mross F, Dieterich H, Seitz R, Ross D, Botstein D, Brown P, Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome, Am J Pathol, 2002, 161(6):1991-1996.
5. Banerjee S, Reis-Filho JS, Ashley S, Steele D, Ashworth A, Lakhani SR, Smith IE, Basal-like breast carcinomas: clinical outcome and response to chemotherapy, J Clin Pathol, 2006, 59(7):729-735.
6. Cheang MCU, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM, Nielsen TO, Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype, Clin Cancer Res, 2008, 14(5):1368-1376.
7. Bertucci F, Finetti P, Rougemont J, Charafe-Jauffret E, Cervera N, Tarpin C, Nguyen C, Xerri L, Houlgatte R, Jacquemier J, Viens P, Birnbaum D, Gene expression profiling identifies molecular subtypes of inflammatory breast cancer, Cancer Res, 2005, 65(6):2170-2178.
8. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC, Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study, JAMA, 2006, 295(21):2492-2502.
9. Carey LA, Dees E, Sawyer L, Gatti L, Moore D, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM, The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes, Clin Cancer Res, 2007, 13(8):2329-2334.
10. Tan DSP, Marchió C, Jones RL, Savage K, Smith IE, Dowsett M, Reis-Filho JS, Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients, Breast Cancer Res Treat, 2008, 111(1):27-44.
11. Kim MJ, Ro JY, Ahn SH, Kim HH, Kim SB, Gong G, Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes, Hum Pathol, 2006, 37(9):1217-1226.
12. Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT, Perou CM, Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma, Mod Pathol, 2006, 19(2):264-271.
13. Diallo-Danebrock R, Ting E, Gluz O, Herr A, Mohrmann S, Geddert H, Rody A, Schaefer KL, Baldus SE, Hartmann A, Wild PJ, Burson M, Gabbert HE, Nitz U, Poremba C, Protein expression profiling in high-risk breast cancer patients treated with high-dose or conventional dose-dense chemotherapy, Clin Cancer Res, 2007, 13(2 Pt 1):488-497.
14. Zainal A, Zainudin M, Nor Saleha I, Malaysian cancer statistics data and figure Peninsular Malaysia, National Cancer Registry, 2006, http://www.makna.org.my/PDF/MalaysiaCancerStatistics.pdf, Last accessed 14/1/2011.
15. Tavassoli F, Devilee P (eds), World Health Organization Classification of Tumours: Pathology and genetics of tumours of the breast and female genital organs, IARC Press, Lyon, 2003.
16. Elston CW, Ellis IO, Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term followup, Histopathology, 1991, 19(5):403-410.
17. American Joint Committee on Cancer, AJCC cancer staging handbook, 2010, www.springer.com/medicine/surgery/cancer+staging?SGWID=0-40654-0-0-0, Last accessed on 14/1/2011.
18. Kononen J, Bubendorf L, Kallioniemi A, Bärlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP, Tissue microarrays for high-throughput molecular profiling of tumor specimens, Nat Med, 1998, 4(7):844-847.
19. Noranizah W, Siti-Aishah MA, Munirah MA, Norazlin MH, Rohaizak M, Naqiyah I, Sharifah NA, Das S, Immunohistochemical expression of vascular endothelial growth factor (VEGF) and p53 in breast lesions, Clin Ter, 2010, 161(2):129-137.
20. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF; American Society of Clinical Oncology; College of American Pathologists, American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer, J Clin Oncol, 2007, 25(1):118-145.
21. Potemski P, Kusinska R, Watala C, Pluciennik E, Bednarek AK, Kordek R, Prognostic relevance of basal cytokeratin expression in operable breast cancer, Oncology, 2005, 69(6):478-485.
22. Tamimi RM, Baer HJ, Marotti J, Galan M, Galaburda L, Fu Y, Deitz AC, Connolly JL, Schnitt SJ, Colditz GA, Collins LC, Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer, Breast Cancer Res, 2008, 10(4):R67.
23. Spitale A, Mazzola P, Soldini D, Mazzucchelli L, Bordoni A, Breast cancer classification according to immunohistochemical markers: clinicopathologic features and short-term survival analysis in a population-based study from the South of Switzerland, Ann Oncol, 2009, 20(4):628-635.
24. Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, Hess KR, Stec J, Ayers M, Wagner P, Morandi P, Fan C, Rabiul I, Ross JS, Hortobagyi GN, Pusztai L, Breast cancer molecular subtypes respond differently to preoperative chemotherapy, Clin Cancer Res, 2005, 11(16):5678-5685.
25. Yang XR, Sherman ME, Rimm DL, Lissowska J, Brinton LA, Peplonska B, Hewitt SM, Anderson WF, Szeszenia-Dabrowska N, Bardin-Mikolajczak A, Zatonski W, Cartun R, Mandich D, Rymkiewicz G, Ligaj M, Lukaszek S, Kordek R, García-Closas M, Differences in risk factors for breast cancer molecular subtypes in a population-based study, Cancer Epidemiol Biomarkers Prev, 2007, 16(3):439-443.
26. Nofech-Mozes S, Trudeau M, Kahn HK, Dent R, Rawlinson E, Sun P, Narod SA, Hanna WM, Patterns of recurrence in the basal and non-basal subtypes of triplenegative breast cancers, Breast Cancer Res Treat, 2009, 118(1):131-137.
27. Foulkes WD, Brunet JS, Stefansson IM, Straume O, Chappuis PO, Bégin LR, Hamel N, Goffin JR, Wong N, Trudel M, Kapusta L, Porter P, Akslen LA, The prognostic implication of the basal-like (cyclin Ehigh/p27low/p53+/ glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer, Cancer Res, 2004, 64(3):830-835.
28. Simpson PT, Reis-Filho JS, Gale T, Lakhani SR, Molecular evolution of breast cancer, J Pathol, 2005, 205(2):248-254.
29. Matos I, Dufloth R, Alvarenga M, Zeferino LC, Schmitt F, p63, cytokeratin 5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas, Virchows Arch, 2005, 447(4):688-694.
30. Honrado E, Osorio A, Milne RL, Paz MF, Melchor L, Cascón A, Urioste M, Cazorla A, Díez O, Lerma E, Esteller M, Palacios J, Benítez J, Immunohistochemical classification of non-BRCA1/2 tumors identifies different groups that demonstrate the heterogeneity of BRCAX families, Mod Pathol, 2007, 20(12):1298-1306.
31. Cheang MCU, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, Perou CM, Ellis MJ, Nielsen TO, Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer, J Natl Cancer Inst, 2009, 101(10):736-750.
32. Yaziji H, Goldstein LC, Barry TS, Werling R, Hwang H, Ellis GK, Gralow JR, Livingston RB, Gown AM, HER-2 testing in breast cancer using parallel tissue-based methods, JAMA, 2004, 291(16):1972-1977.
33. Dowsett M, Bartlett J, Ellis IO, Salter J, Hills M, Mallon E, Watters AD, Cooke T, Paish C, Wencyk PM, Pinder SE, Correlation between immunohistochemistry (Hercep Test) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres, J Pathol, 2003, 199(4):418-423.
34. Pintens S, Neven P, Drijkoningen M, Van Belle V, Moerman P, Christiaens MR, Smeets A, Wildiers H, Van den Bempt I, Triple negative breast cancer: a study from the point of view of basal CK5/6 and HER-1, J Clin Pathol, 2009, 62(7):624-628.
35. Laakso M, Tanner M, Nilsson J, Wiklund T, Erikstein B, Kellokumpu-Lehtinen P, Malmström P, Wilking N, Bergh J, Isola J, Basoluminal carcinoma: a new biologically and prognostically distinct entity between basal and luminal breast cancer, Clin Cancer Res, 2006, 12(14 Pt 1):4185-4191.
36. Geisler S, Lønning PE, Aas T, Johnsen H, Fluge O, Haugen DF, Lillehaug JR, Akslen LA, Børresen-Dale AL, Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer, Cancer Res, 2001, 61(6):2505-2512.
37. Greenblatt MS, Chappuis PO, Bond JP, Hamel N, Foulkes WD, TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germ-line mutations: distinctive spectrum and structural distribution, Cancer Res, 2001, 61(10):4092-4097.
38. Foulkes WD, Stefansson IM, Chappuis PO, Bégin LR, Goffin JR, Wong N, Trudel M, Akslen LA, Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer, J Natl Cancer Inst, 2003, 95(19):1482-1485.
39. Laakso M, Loman N, Borg A, Isola J, Cytokeratin 5/14-positive breast cancer: true basal phenotype confined to BRCA1 tumors, Mod Pathol, 2005, 18(10):1321-1328.
40. Russo J, Lynch H, Russo IH, Mammary gland architecture as a determining factor in the susceptibility of the human breast to cancer, Breast J, 2001, 7(5):278-291.
41. Rakha EA, Reis-Filho JS, Ellis IO, Basal-like breast cancer: a critical review, J Clin Oncol, 2008, 26(15):2568-2581.